title: [Cancer immunotherapy].
abstract: A revision of the most promising clinical assays suggest that immunotherapy is useful for a certain number of selected patients. Immunotherapy cannot be used alone for primary treatment of cancer, excepting perhaps as local immunotherapy for readily accessible tumors. The most important role of immunotherapy is to be found in combination with other kinds of therapy, considering that it may restrain effectively hidden micrometastases that are the cause of relapse and fatal outcome. However, it is necessary to recognize that immunotherapy has shown until now a limited therapeutic efficacy.
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007167:Immunotherapy / Q000009:adverse effects / Q000145:classification* / Q000639:trends; D009367:Neoplasm Staging; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D014612:Vaccines / Q000009:adverse effects / Q000145:classification
chemical_list: D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D014612:Vaccines
vernacular_title: Inmunoterapia oncológica.